A daily oral medication combined with chemotherapy has caused tumors to shrink and, in some cases, become undetectable during early clinical evaluations, according to findings discussed on Thursday.
Experts tracking the data called it the biggest therapeutic advance for the disease in decades.
BBC News reported that in about one in 12 patients given daraxonrasib alongside chemotherapy, the cancer vanished from scans entirely. Tumors stopped growing in nearly all of the 61 participants involved in the trial.
The participants had recently received diagnoses of advanced pancreatic cancer that had metastasized to other parts of the body. Most patients with advanced forms of the illness survive for months rather than years, and the condition holds the lowest survival rate among common cancers in the UK.
The treatment works by focusing on a mutated gene protein often nicknamed the Death Star because researchers struggled for decades to find a way to attack it. More than nine out of ten pancreatic tumors carry this mutation, which sends persistent signals telling cancer cells to multiply.

Daraxonrasib binds directly to the protein to shut off those signals. The U.S. Food and Drug Administration approved the medication in August 2026 for certain adult patients with metastatic pancreatic cancer.
The latest study tested the drug combined with standard chemotherapy drugs gemcitabine and nab-paclitaxel as a first-line treatment. The findings were presented at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain, according to data from Revolution Medicines.
Researchers followed patients for an average of 18 months during the evaluation. Data showed that 76.6% of patients who received the combination therapy survived beyond 12 months.

| Metric | Trial Results |
|---|---|
| Tumor growth halted | 90% of patients |
| Tumors shrank or disappeared | 60.7% of patients |
| Tumors undetectable on scans | 8.2% of patients (1 in 12) |
| Survival past 12 months | 76.6% of patients |
Michelle Mitchell, chief executive of Cancer Research UK, described the medication as the biggest leap forward seen in decades for patients facing the condition. She told The Telegraph that more than 11,000 people receive diagnoses in the UK annually, while more than 10,000 die from it.
“What this new drug has done is it’s found a way of drugging the undruggable. We are finally seeing progress in pancreatic cancer which is so long overdue.”
Dr Sam Godfrey told BBC News.
Physicians said that the results remain early. Dr Wungki Park of the Memorial Sloan Kettering Cancer Center in the US said that the findings show deeper responses and a near-doubling in disease control duration.
“We are beginning to see not only a higher percentage of tumour response rates, but also deeper responses and a near doubling in the duration of disease control, which may eventually translate into longer survival.”